Observational studyThe Indian journal of medical research2026
Glycated haemoglobin (HbA1c) levels and motor symptoms in Parkinson's disease.
Observational study in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Emerging evidence indicates a complex relationship between glycated haemoglobin (HbA1c) levels and motor symptom severity in Parkinson's disease. Both elevated (>6.1%) and low (<5.3%) HbA1c have been linked to increased disability. This study examined the association between HbA1c levels and motor symptoms in patients with Parkinson's disease from Jodhpur, India. Methods A cross-sectional observational study was conducted at the department of Neurology, Mathura Das Mathur Hospital, Jodhpur between March 2023 and February 2024. One hundred patients with Parkinson's disease patients fulfilling the UK Parkinson's Disease Society Brain Bank (UKPDSBB) criteria were enrolled. Participants underwent HbA1c testing, motor evaluation with the Unified Parkinson's Disease Rating Scale (UPDRS III) in ON and OFF states, and cognitive screening with the Montreal Cognitive Assessment (MoCA). Patients were categorised into three groups based on HbA1c: ≤4.9% (Low), 5.0-5.9% (Normal-to-Prediabetic), and ≥6.0% (High). Disease duration and medication history were also recorded. Results No significant group differences were found for age, sex, body mass index (BMI), or disease duration, between the three groups, based on HbA1c levels. UPDRS and MoCA scores differed significantly across HbA1c categories (P<0.001). Higher HbA1c strongly correlated with worse motor outcomes (UPDRS ON: Spearman's ρ=0.90; OFF: ρ=0.84) and poorer cognition (MoCA: ρ= -0.79). Interpretation and conclusions Elevated HbA1c levels were significantly associated with greater motor impairment and cognitive dysfunction in Parkinson's disease. These findings highlight the potential role of metabolic dysregulation in progression of Parkinson's disease and underscore the need for longitudinal studies to clarify causal links and therapeutic implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.